カルナバイオサイエンス株式会社 · Pharmaceutical · FY ends Dec
| # | Shareholder | Shares | Stake | Value | Dividends |
|---|---|---|---|---|---|
| 1 | MSIP Client Securities | 955,612 | 4.99% | — | — |
| 2 | 川村 剛 | 555,500 | 2.90% | — | — |
| 3 | Ono Pharmaceutical Co., Ltd. | 504,500 | 2.63% | — | — |
| 4 | 上原 俊彦 | 500,000 | 2.61% | — | — |
| 5 | 堀田 和男 | 468,800 | 2.44% | — | — |
| 6 | 吉野 公一郎 | 333,900 | 1.74% | — | — |
| 7 | 小川 義水 | 255,000 | 1.33% | — | — |
| 8 | BNY GCM CLIENT ACCOUNT JPRD AC ISG | 195,241 | 1.02% | — | — |
| 9 | BNYM SA/NV FOR BNYM FOR BNYM GCM CLIENT ACCTS M ILM FE | 180,304 | 0.94% | — | — |
| 10 | Takaaki Suzuki | 149,000 | 0.77% | — | — |
| Name | Title | Shares | Value | Pay |
|---|---|---|---|---|
| 吉野 公一郎 | President & Representative Director | 380,100 | — | — |
| 澤 匡明 | Director | 106,000 | — | — |
| 山本 詠美 | Director | 54,600 | — | — |
| 有村 昭典 | Director | 16,500 | — | — |
| 増岡 国久 | Director | 4,000 | — | — |
| 有田 篤雄 | Director | 8,000 | — | — |
| 松井 隆雄 | Director | — | — | — |
| 鈴木 香 | Director | — | — | — |
| 寺田 勝基 | Director | — | — | — |
Pay is shown only for officers whose pay of ¥100 million or more is disclosed individually.
| Fiscal year | Price | EPS | P/E | Dividend | Shares issued |
|---|---|---|---|---|---|
| FY ending Dec 2025 | — | ¥-113.62 | — | — | 19,150,500 |
| FY ending Dec 2024 | — | ¥-121.64 | — | — | 19,107,500 |
| FY ending Dec 2023 | — | ¥-68.62 | — | — | 17,151,900 |
| FY ending Dec 2022 | — | ¥-99.10 | — | — | 14,218,300 |
| FY ending Dec 2021 | ¥2,122 | ¥-42.10 | — | — | 13,313,400 |
| FY ending Dec 2020 | ¥2,122 | ¥-90.33 | — | — | 12,407,100 |
| FY ending Dec 2019 | ¥2,122 | ¥76.05 | 27.9x | — | 11,654,500 |
| FY ending Dec 2018 | ¥2,122 | ¥-125.02 | — | — | 10,139,600 |
| FY ending Dec 2017 | ¥2,122 | ¥-78.53 | — | — | 9,551,300 |
| FY ending Dec 2016 | — | ¥-31.64 | — | — | 9,239,000 |